Oscar Health: Barclays, UBS, And Wells Fargo Downgraded, But The Real Story Says Buy

Oscar Health (OSCR) is rated a 'Buy' in this analysis, despite recent bearish theses from Wells Fargo and Barclays citing rising medical costs and 2025 pricing concerns, with Barclays setting a $17 target. The bullish outlook is predicated on OSCR's strong revenue growth (82% CAGR FY20-FY24), improved FY24 profitability, and projected SG&A reductions to 16% by FY27. Further supporting the thesis are a balanced Medical Loss Ratio (81.5%), a high Net Promoter Score (66), strategic expansion into the high-potential ICHRA market (75M TAM), and AI-driven cost efficiencies, including an 8.5% reduction in repeat ER visits. While acknowledging regulatory risks from ACA reliance and competition, the company's reaffirmed FY25 outlook and long-term strategic shifts are highlighted as key to its potential outperformance.

Analysis

Oscar Health (OSCR) presents a conflicting investment profile, with a bullish internal outlook clashing with recent bearish theses from Wells Fargo and Barclays. The primary concerns cited by analysts revolve around rising medical costs, inadequate 2025 pricing, and significant regulatory risk, given that 98% of OSCR's revenue is derived from ACA premiums. This dependency is underscored by a UBS forecast predicting a potential 30% decline in ACA enrollment by 2026. However, the company's performance metrics offer a strong counter-narrative. OSCR has demonstrated an 82% compound annual revenue growth rate from FY20 to FY24 and achieved profitability in FY24. Operational efficiency is improving, with the SG&A expense ratio falling from 34.3% in FY20 to 19.1% in FY24, and management is guiding for a further reduction to 16% by FY27. Key insurance metrics are also robust, including a stable Medical Loss Ratio of 81.5% and a Net Promoter Score of 66, significantly above the industry average. To mitigate ACA dependency, management is executing a strategic pivot towards the large-TAM Individual Coverage Health Reimbursement Arrangement (ICHRA) market and leveraging proprietary AI to reduce costs, evidenced by an 8.5% reduction in repeat ER visits in a pilot program. Despite external skepticism and mixed valuation signals, management has reaffirmed its full-year 2025 guidance, with revenue projected between $11.2B and $11.3B, signaling confidence in its growth trajectory.

Key Decisions for Investors

• Investors should evaluate whether OSCR's strategic diversification into the ICHRA market and its AI-driven cost efficiencies can sufficiently offset the considerable regulatory risks associated with its high dependence on the ACA market.
• Monitor progress on the company's SG&A expense ratio and any updates on member growth within the ICHRA segment, as these are the primary catalysts for the long-term margin expansion and revenue diversification thesis.
• Given the opposing views from major analysts and mixed valuation metrics, positions in OSCR should be considered higher risk; the reaffirmed FY25 guidance provides a near-term data point, but the investment case relies heavily on successful long-term execution of its strategic pivot.